Results from the study, “Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis,” were recently published in the Multiple Sclerosis Journal.
Multiple sclerosis (MS) is a multifactorial disease associated with both genetic and environmental risk factors. Smoking, in particular, has been linked to numerous aspects of MS, including its development and progression.
In a previous study, the research team looked at how smoking influences the relapse rate in RRMS patients being treated with interferon (IFN)-beta. From more than 800 patients, they found that smoking one pack per day (about 20 cigarettes) essentially interfered with the positive effect of the IFN-beta treatment and increased the relapse rate by 27%.
The researchers then questioned whether the same was true for other treatments.
Tysabri, developed by Biogen, is a monoclonal antibody that targets the alpha-4 integrin protein. By interfering with this molecule, the therapy prevents white blood cells from moving into the central nervous system, suppressing the immune reaction that contributes to MS symptoms.
In the study, 355 Tysabri-treated RRMS patients from the Danish Multiple Sclerosis Centre were assessed. To gather information on smoking habits and body mass index, the patients filled out a 100-question survey. Data was collected between the start of the treatment and a two-year follow-up visit.
Results showed that smoking one pack of cigarettes per day increases the relapse rate by 38% in RRMS patients on Tysabri.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?